Bifogade filer
OptiCept Technologies Q3 Report 2024 EN
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Material |
| Industri | Forskning & Utveckling |
OptiCept Technologies AB (publ),(ticker: OPTI) today published its Interim Report Q3 for 2024 (January – September 2024) which is available on the company's website: https://investor.opticept.se/finansiell-information/finansiella-rapporter/
SIGNIFICANT EVENTS Q3 2024 SIGNIFICANT EVENTS AFTER PERIOD END
• OptiCept Submits Patent Application and Strengthens its IP-portfolio for Vacuum Impregnation focused on cuttings
• OptiCept Technologies signs agreement with leading olive oil producer in Spain
• OptiCept Technologies signs lease agreement with innovative olive oil producer in Spain
• OptiCept signs additional rental agreement with olive oil producer in Spain
• OptiCept signs lease agreement with world-renowned wine producer in France
• New research confirms that PEF technology from OptiCept increases the shelf life of freshly squeezed juice
• OptiCept and Saab Sign Memorandum of Understanding For Collaboration in Thailand • The olive oil producer La Salud confirms a conditional order to OptiCept
SIGNIFICANT EVENTS AFTER PERIOD END
• OptiCept Technologies announces a change of CFO
• OptiCept Technologies AB announces Nomination Committee for the Annual General Meeting 2025
• OptiCept Signs Rental Agreement with Leading Juice Producer in Costa Rica
• OptiCept Technologies intends to decide on a rights issue of shares of approximately SEK 80.4 million and brings forward the publication of the Q3 report
| FINANCIAL OVERVIEW | ||||
| KSEK (unless otherwise stated)* | Q3 (Jul-Sep) | Q1-Q3 (Jan-Sep) | ||
| 2024 | 2023 | 2024 | 2023 | |
| Net revenue** | 4 119 | 1 149 | 17 227 | 8 700 |
| Operating Income | -12 471 | -17 768 | -38 591 | -50 536 |
| Result for the period | -13 150 | -20 845 | -38 168 | -58 570 |
| Open orders | 50 960 | 29 686 | 50 960 | 29 686 |
| Reported EBITDA | -9 944 | -12 749 | -27 691 | -35 602 |
| Net result for the period | 380 669 | 391 413 | 380 669 | 391 413 |
| Cash & cash equivalents | 4 559 | 12 185 | 4 559 | 12 185 |
| Equity | 340 399 | 346 095 | 340 399 | 346 095 |
| Equity ratio (%) | 89% | 88% | 89% | 88% |
| Average number of shares in the period | 45 982 664 | 30 843 265 | 45 982 664 | 30 096 754 |
| Number of shares at the end of the period | 51 496 408 | 30 843 265 | 51 496 408 | 30 843 265 |
| Earnings per share before and after dilution (SEK) | -0,29 | -0,68 | -0,83 | -1,95 |
| Cash flow from operating activities | -11 041 | -16 827 | -32 802 | -68 907 |
| Total Cash flow | 537 | -14 318 | -9 556 | -82 525 |
| * Rounding may occur so that in some cases the amounts do not add up | ||||
“The breakthroughs and milestones we have achieved in recent quarters have significantly accelerated our journey toward becoming an established commercial company. OptiCept is now in the most exciting phase in the company’s history, and with strengthened financing for our continued growth in place, we eagerly look forward to what lies ahead”, said Thomas Lundqvist, CEO at OptiCept Technologies.